Dark

ALNY
Alnylam Pharmaceuticals, Inc.
stock NASDAQ

At Close

Jun 2, 2025 3:59:59 PM EDT

306.18USD+0.532%(+1.62)1,132,004

0.00Bid 0.00Ask 0.00Spread

Pre-market

0.00USD-100.000%(-304.56)0

After-hours

Jun 2, 2025 4:48:30 PM EDT

304.00USD-0.712%(-2.18)106,060

OverviewOptionsHistoricalExchangesShortsNews

Jan 28, 2022

06:22AM EST SVB Leerink Maintains Market Perform on Alnylam Pharmaceuticals, Raises Price Target to $109 Benzinga

Jan 24, 2022

08:38AM EST Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial Results Business Wire

Jan 21, 2022

09:23AM EST Alnylam' Reveals Detailed 18-Month Data From Vutrisiran Trial In Inherited Disease Benzinga

08:08AM EST The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective Benzinga

07:54AM EST Alnylam: HELIOS-A Phase 3 Study Of Vutrisiran Meets All RTTNews

07:35AM EST ALNY:HELIOS-A Results Show Improvement In Neuropathy Impairment &quality Of Life Observed With Vutrisiran At 9 Months RTTNews

07:33AM EST Alnylam Highlights 18-Month Results From HELIOS-A Phase 3 Study Of Vutrisiran: All Secondary Endpoints Were Met; BZ NOTE: Co. Previously Announced All Primary, Secondary Endpoints Met On 9-Month Basis; However, Release Today Does Not Mention Primary Benzinga

07:30AM EST Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy Business Wire

05:16AM EST What 10 Analyst Ratings Have To Say About Alnylam Pharmaceuticals Benzinga

Jan 20, 2022

06:19AM EST HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $350 Benzinga

Jan 18, 2022

09:07AM EST n-Lorem Foundation Reports Partnership With Alnylam To Expand Technology Access To RNAi Therapeutics For Patients With Nano-Rare Diseases, No Terms Disclosed Benzinga

08:55AM EST Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $215 Benzinga

Jan 16, 2022

04:38PM EST The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week Benzinga

Jan 14, 2022

07:00AM EST Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Socit Francophone du Nerf Priphrique Annual Meeting Business Wire

Jan 9, 2022

08:24PM EST Alnylam Pharmaceuticals Inc. (ALNY) said that it expects its full year 2021 non-GAAP operating loss to be substantially improved relative to the prior year. RTTNews

01:07PM EST Alnylam Pharmaceuticals Sees FY 2021 Revenue $662M vs $814.2M Est Benzinga

01:00PM EST Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates Business Wire

Jan 6, 2022

08:45AM EST Alnylam, Novartis Enter Research Collaboration To Provide RTTNews

07:35AM EST Alnylam Announces Collaboration With Novartis To Explore Targeted Therapy To Restore Liver Function RTTNews

04:51AM EST Novartis Announced Three-Year Collaboration With Alnylam to Explore Targeted Therapy to Restore Liver Function Benzinga

Jan 4, 2022

07:55AM EST Alnylam Pharmaceuticals, Inc. (ALNY), a RNAi therapeutics company, said on Tuesday that it has elevated Akshay Vaishnaw as its new President. RTTNews

07:37AM EST Alnylam Announces Promotion Of Dr. Akshay Vaishnaw To President Benzinga

07:34AM EST Alnylam Pharma Promotes Akshay Vaishnaw To President RTTNews

07:30AM EST Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President Business Wire

Jan 3, 2022

10:12AM EST What 9 Analyst Ratings Have To Say About Alnylam Pharmaceuticals Benzinga

07:22AM EST Piper Sandler Upgrades Alnylam Pharmaceuticals to Overweight, Raises Price Target to $208 Benzinga

07:00AM EST Alnylam to Webcast Presentation at 40th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 23, 2021

08:20AM EST FDA Approves Alnylam - Novartis' Leqvio As the First siRNA To Reduce Bad Cholesterol Benzinga

07:29AM EST The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review Benzinga

Dec 22, 2021

04:26PM EST Alnylam Pharma Reports Comments On FDA Approval Of Leqvio Approved To Reduce Low-Density Lipoprotein Cholesterol Benzinga

04:23PM EST Alnylam Comments on FDA Approval of Leqvio(r), the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C Business Wire

07:37AM EST Alnylam Pharmaceuticals, Inc. (ALNY) has submitted a Clinical Trial Authorization application to The Medicines and Healthcare Products Regulatory Agency in the United Kingdom to begin a phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein for the treatment of Alzheimer's disease and cerebral amyloid angiopathy. RTTNews

07:03AM EST Alnylam Submits CTA Application To MHRA In UK For ALN-APP For Alzheimer's Disease And Cerebral Amyloid Angiopathy RTTNews

07:01AM EST Alnylam Submits CTA Application For ALN-APP, An Investigational RNAi Therapeutic For The Treatment Of Alzheimer's Disease And Cerebral Amyloid Angiopathy Benzinga

Dec 21, 2021

04:49PM EST Alnylam Pharma Highlights Publication Of Third Annual Patient Access Philosophy Report Showing Access To Approved Therapies As Co. Enters New Geographies Benzinga

04:30PM EST Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access to Approved Therapies as Company Enters New Geographies Business Wire

08:12AM EST The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail Benzinga

Dec 20, 2021

04:01PM EST Alnylam Initiates Phase 2 Study Of Lumasiran In Patients With Recurrent Kidney Stone Disease Benzinga

07:11AM EST Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout Benzinga

07:05AM EST Alnylam Pharma Submits CTA Application For ALN-XDH In The United Kingdom To Initiate Phase 1/2 Study RTTNews

07:00AM EST Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout Business Wire

Dec 14, 2021

07:48AM EST Alnylam Submits Applications In U.S, EU To Support Label RTTNews

07:19AM EST Alnylam Submits Regulatory Applications To The FDA And European Medicines Agency To Support Label Expansion For OXLUMO For The Treatment Of Advanced Primary Hyperoxaluria Type 1 Benzinga

07:06AM EST Alnylam Submits Applications To FDA And EMA To Support Label Expansion For OXLUMO For Advanced PH1 Treatment RTTNews

07:00AM EST Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO(r) for the Treatment of Advanced Primary Hyperoxaluria Type 1 Business Wire

Dec 9, 2021

08:41AM EST Direxion Launches mRNA ETF (MSGR) PR Newswire

Dec 6, 2021

06:07AM EST The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More Benzinga

Dec 2, 2021

08:00AM EST Alnylam Ranks #1 in Boston Globe's Top Places to Work List for 2021 Business Wire

Nov 23, 2021

08:00AM EST Alnylam to Webcast Presentations at Upcoming Investor Conferences Business Wire

Nov 22, 2021

11:12AM EST Expert Ratings For Alnylam Pharmaceuticals Benzinga

10:06AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021 Benzinga

08:05AM EST Goldman Sachs Upgrades Alnylam Pharmaceuticals to Buy, Announces $273 Price Target Benzinga

07:30AM EST 10 Biggest Price Target Changes For Monday Benzinga

06:03AM EST Needham Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $205 Benzinga

05:17AM EST RBC Capital Upgrades Alnylam Pharmaceuticals to Outperform, Raises Price Target to $225 Benzinga

Nov 19, 2021

07:25AM EST Alnylam Pharmaceuticals, Inc. (ALNY) said it expects to achieve FDA approval for Vutrisiran in early 2022 for the treatment of the polyneuropathy of hATTR amyloidosis in adults. The PDUFA date is April 14, 2022. The company plans to launch vutrisiran in the U.S. in early 2022. RTTNews

07:10AM EST Alnylam Pharma To Highlight 2022 Product, Pipeline Goals At R&D Today Friday, Starting At 8:30 a.m. EST Benzinga

07:07AM EST Alnylam Plans To Initiate Phase 3 Study In Patients With Stargardt Disease In Late 2022 RTTNews

07:00AM EST Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day Business Wire

Nov 13, 2021

08:00AM EST Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021 Business Wire

Nov 12, 2021

08:00AM EST Alnylam to Webcast Virtual R&D Day Business Wire

Nov 8, 2021

07:11AM EST Alnylam Pharmaceuticals Initiates KARDIA-2 Phase 2 Study Of Investigational Zilebesiran (ALN-AGT) In Patients With Inadequately Controlled Hypertension Benzinga

07:06AM EST Alnylam Initiates KARDIA-2 Phase 2 Study Of Zilebesiran In Patients With Hypertension RTTNews

07:00AM EST Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension Business Wire

Nov 5, 2021

01:30PM EDT Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 Business Wire

Nov 1, 2021

04:00PM EDT Alnylam Named a Science Magazine Top Employer for Third Consecutive Year Business Wire

12:15PM EDT Where Alnylam Pharmaceuticals Stands With Analysts Benzinga

06:10AM EDT Oppenheimer Upgrades Alnylam Pharmaceuticals to Outperform, Announces $200 Price Target Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 29, 2021

09:36AM EDT Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $226 Benzinga

08:19AM EDT Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $200 Benzinga

Oct 28, 2021

12:21PM EDT SVB Leerink Maintains Market Perform on Alnylam Pharmaceuticals, Raises Price Target to $108 Benzinga

08:32AM EDT Alnylam Pharmaceuticals Reaffirms FY21 Combined Net Product Revenues $640M-$665M Benzinga

08:32AM EDT Alnylam Pharmaceuticals Q3 Adj. EPS $(1.51) Beats $(1.57) Estimate, Sales $187.63M Miss $218.69M Estimate Benzinga

08:26AM EDT The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug Benzinga

08:00AM EDT Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity Business Wire

07:55AM EDT Alnylam Announces Planned CEO Leadership Transition Business Wire

04:08AM EDT Earnings Scheduled For October 28, 2021 Benzinga

Oct 27, 2021

04:15PM EDT Alnylam Reports Topline 18-Month Results From HELIOS-A Phase 3 Study Of Vutrisiran In Patients With hATTR Amyloidosis With Polyneuropathy Benzinga

04:00PM EDT Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy Business Wire

Oct 24, 2021

11:45AM EDT The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More Benzinga

Oct 18, 2021

08:25AM EDT Alnylam Pharmaceuticals Inc.'s (ALNY) GIVLAARI or givosiran has now received a positive recommendation for reimbursement from the Canadian Agency for Drugs and Technologies in Health or CADTH, the company said in a statement. RTTNews

08:13AM EDT Alnylam Pharma Reports Received Positive Reimbursement Recommendation From Canadian Agencies For Drugs And Technology In Health For Use Of GIVLAARI As Treatment Of Acute Hepatic Prophyria Benzinga

08:04AM EDT Alnylam Receives Positive Recommendation From CADTH For Use Of GIVLAARI For Treatment Of Acute Hepatic Porphyria RTTNews

08:00AM EDT Agencies for Drugs and Technology in Health (CADTH) for use of GIVLAARI(r) for the Treatment of Acute Hepatic Porphyria (AHP) in Adults PR Newswire

Oct 14, 2021

08:00AM EDT Alnylam to Webcast Conference Call Discussing Third Quarter 2021 Financial Results Business Wire

Oct 13, 2021

07:33AM EDT Alnylam Announces Launch Of Alnylam Challengers RTTNews

07:30AM EDT Alnylam Announces Launch of "Alnylam Challengers," a Signature Community Impact Program to Improve Health Access to Underserved Communities Business Wire

Oct 12, 2021

12:29PM EDT Where Alnylam Pharmaceuticals Stands With Analysts Benzinga

08:03AM EDT Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $242 Benzinga

Oct 4, 2021

02:07PM EDT Analyst Ratings For Alnylam Pharmaceuticals Benzinga

10:16AM EDT UBS Upgrades Alnylam Pharmaceuticals to Buy, Raises Price Target to $215 Benzinga

Sep 29, 2021

07:30AM EDT Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society Business Wire

Sep 28, 2021

04:00PM EDT Alnylam to Webcast Presentation at Chardan Virtual 5th Annual Genetic Medicines Conference Business Wire

08:06AM EDT Alnylam Pharmaceuticals Announces ONPATTRO Is Now Reimbursed In Canada For Hereditary Transthyretin (TTR)-Mediated Amyloidosis (hATTR) Benzinga

08:04AM EDT Alnylam Pharma Says ONPATTRO Now Reimbursed In Canada For Hereditary Transthyretin-Mediated Amyloidosis RTTNews

08:00AM EDT ONPATTRO(r) (patisiran) Now Reimbursed in Canada For the Treatment of PR Newswire

Sep 13, 2021

07:30AM EDT RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (ALNY) announced Monday the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vutrisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with polyneuropathy. RTTNews

07:11AM EDT Alnylam Submits Marketing Authorization Application To European Medicines Agency For Investigational Vutrisiran For The Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy Benzinga

07:04AM EDT Alnylam Submits MAA To EMA For Vutrisiran For Hereditary ATTR Amyloidosis With Polyneuropathy RTTNews

07:00AM EDT Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy Business Wire

Sep 10, 2021

09:37AM EDT Alnylam Pharmaceuticals Sponsored Study Titled 'Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program' Posted To ClinicalTrials.gov; Study Is Recruiting Benzinga

Sep 7, 2021

07:08AM EDT Alnylam Presents Addl 9-Month Data From HELIOS-A Phase 3 Study Of Vutrisiran At EU-ATTR Amyloidosis Meeting RTTNews

07:00AM EDT Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting Business Wire

Sep 1, 2021

04:00PM EDT Alnylam to Webcast Presentations at Upcoming September Investor Conferences Business Wire

Aug 31, 2021

10:52PM EDT Novartis (NVS) and United Kingdom's National Health Service reached an agreement that will enable broad access to the Swiss drug giant's anti-cholesterol drug Leqvio or inclisiran for hundreds of thousands of high-risk cardiovascular patients. RTTNews

Aug 27, 2021

10:10AM EDT BMO Capital Maintains Market Perform on Alnylam Pharmaceuticals, Raises Price Target to $196 Benzinga

Aug 19, 2021

03:23PM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2021 Benzinga

Aug 13, 2021

06:14AM EDT HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $250 Benzinga

Aug 12, 2021

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

Aug 11, 2021

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

Aug 10, 2021

07:55AM EDT The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts Benzinga

Aug 9, 2021

07:35AM EDT Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy Benzinga

07:04AM EDT Alnylam Completes Enrollment In HELIOS-B Phase 3 Study Of Vutrisiran RTTNews

07:00AM EDT Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy Business Wire

Aug 6, 2021

07:42AM EDT The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO Benzinga

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

Aug 4, 2021

10:34AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2021 Benzinga

08:24AM EDT Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $234 Benzinga

08:12AM EDT Barclays Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $216 Benzinga

05:23AM EDT Piper Sandler Downgrades Alnylam Pharmaceuticals to Neutral, Announces $181 Price Target Benzinga

Aug 3, 2021

09:11AM EDT Alnylam Pharma Increases 2021 Combined Net Product RTTNews

08:12AM EDT Alnylam Pharmaceuticals Q2 EPS $(1.30) Beats $(1.60) Estimate, Sales $220.55M Beat $193.18M Estimate Benzinga

08:06AM EDT Alnylam Pharma Q2 Non-GAAP Net Loss/shr Narrows To $1.30 From $1.67 Prior Year RTTNews

08:00AM EDT Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity Business Wire

03:52AM EDT Earnings Scheduled For August 3, 2021 Benzinga

Jul 30, 2021

09:29AM EDT PeptiDream Inks $2.2B Deal To Broaden Alnylam's siRNA Delivery Scope Benzinga

07:54AM EDT The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs Benzinga

Jul 29, 2021

05:01PM EDT Alnylam Pharma Reports Collaboration With PeptiDream To Discover, Develop Peptide-siRNA Conjugates For Targeted Delivery Of RNAi Therapeutics to Broader Range Of Extrahepatic Tissues Benzinga

05:00PM EDT Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues Business Wire

10:21AM EDT Alnylam's Lumasiran Substantially Reduces Plasma Oxalate Levels PH1 Patients With Severe Renal Impairment Benzinga

08:40AM EDT Alnylam Reports Positive Results From Phase 3 Study Of RTTNews

07:25AM EDT Alnylam Reports Positive Topline Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 Benzinga

07:18AM EDT Alnylam Reports Positive Results From Phase 3 Study Of Lumasiran In Patients With Advanced Primary Hyperoxaluria Type 1 RTTNews

07:00AM EDT Alnylam Reports Positive Topline Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 Business Wire

Jul 21, 2021

08:00AM EDT Alnylam to Webcast Conference Call Discussing Second Quarter 2021 Financial Results Business Wire

07:52AM EDT The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay Benzinga

Jul 16, 2021

08:23AM EDT Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $224 Benzinga

Jul 13, 2021

08:05AM EDT The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data Benzinga

Jul 12, 2021

10:14AM EDT Stocks That Hit 52-Week Highs On Monday Benzinga

Jun 30, 2021

07:06AM EDT Alnylam Pharma Initiates KARDIA-1 Phase 2 Study Of Zilebesiran In Patients With Mild-to-Moderate Hypertension RTTNews

07:03AM EDT Alnylam Initiates KARDIA-1 Phase 2 Study Of Zilebesiran (ALN-AGT) In Patients With Mild-To-Moderate Hypertension Benzinga

Jun 28, 2021

11:25AM EDT Chardan Research Maintains Buy Rating On Alnylam Pharmaceuticals, Price Target $190. Benzinga

11:23AM EDT CORRECTION: Alnylam Ticker Is 'ALNY' Benzinga

Jun 24, 2021

07:43AM EDT RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (ALNY) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for vutrisiran, an investigational RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. RTTNews

07:10AM EDT Alnylam Announces FDA Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis Benzinga

07:04AM EDT Alnylam Says FDA Accepted NDA For Vutrisiran For Treatment Of Polyneuropathy Of Hereditary ATTR Amyloidosis RTTNews

07:00AM EDT Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis Business Wire

Jun 23, 2021

07:35AM EDT The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway Benzinga

07:00AM EDT Alnylam to Host Eighth Annual "RNAi Roundtable" Webcast Series Business Wire

Jun 7, 2021

07:34AM EDT Alnylam Announces Positive Results From Phase 3b Study Conducted To Evaluate Safety, Efficacy And PK Of Patisiran RTTNews

07:33AM EDT Alnylam Highlights Data From ATTR Amyloidosis Programs At Peripheral Nerve Society's 2021 Annual Meeting Benzinga

07:30AM EDT Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society's 2021 Annual Meeting Business Wire

Jun 1, 2021

07:06AM EDT Alnylam Pharma Completes Enrollment In APOLLO-B Phase 3 Study Of Patisiran In ATTR Patients With Cardiomyopathy RTTNews

07:06AM EDT Alnylam Completes Enrollment In APOLLO-B Phase 3 Study Of Patisiran In Transthyretin-Mediated Amyloidosis Patients With Cardiomyopathy Benzinga

07:00AM EDT Alnylam Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy Business Wire

May 26, 2021

04:00PM EDT Alnylam to Webcast Presentations at Upcoming June Investor Conferences Business Wire

May 11, 2021

07:05AM EDT Alnylam Pharma Begins Clinical Study Of Biannual Dosing Regimen Of Vutrisiran For Transthyretin-mediated Amyloidosis RTTNews

07:00AM EDT Alnylam Announces New Advances in ATTR Amyloidosis Program Business Wire

May 4, 2021

08:00AM EDT Alnylam to Webcast Presentations at Upcoming May Investor Conferences Business Wire

May 3, 2021

07:08AM EDT Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO Benzinga

07:07AM EDT Alnylam Pharma Announces Positive Early Results From ILLUMINATE-A Phase 3 Study Of OXLUMO RTTNews

07:00AM EDT Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO(r) (lumasiran) Business Wire

Apr 30, 2021

07:44AM EDT Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $205 Benzinga

Apr 29, 2021

08:23AM EDT Alnylam Pharmaceuticals Q1 Adj. EPS $(1.64) Beats $(1.75) Estimate Benzinga

08:15AM EDT The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx Benzinga

08:05AM EDT Alnylam Pharma Q1 GAAP Loss Per Share $1.71; Non-GAAP Loss Per Share $1.64 RTTNews

08:00AM EDT Alnylam Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity Business Wire

04:10AM EDT Earnings Scheduled For April 29, 2021 Benzinga

Apr 24, 2021

09:24AM EDT The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx Benzinga

Apr 19, 2021

02:01PM EDT Alnylam Presents Results From HELIOS-A Phase 3 Study Of Investigational Vutrisiran Benzinga

02:00PM EDT Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran Business Wire

Apr 15, 2021

08:00AM EDT Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results Business Wire

Apr 12, 2021

05:04PM EDT Alnylam Pharma 8-K Shows Co. Received Subpoena From US Dept. Of Justice, US Attorney's Office Requiring Production Of Documents Related To Marketing, Promotion Of ONPATTRO In US; Co. Is Preparing Response Benzinga

Apr 11, 2021

10:28AM EDT Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension Business Wire

Apr 8, 2021

09:04AM EDT Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront Benzinga

Apr 6, 2021

08:00AM EDT Alnylam to Webcast Presentation at 20th Annual Needham Virtual Healthcare Conference Business Wire

Apr 1, 2021

03:41PM EDT Alnylam Pharmaceuticals shares were trading higher after the company announced its ILLUMINATE-A Phase 3 study results for Lumasiran were published in the New England Journal of Medicine. Benzinga

09:37AM EDT Alnylam's Oxalate-Lowering Therapy Shows Significant Clinical Benefit; Data Published In New England Journal Of Medicine Benzinga

Mar 31, 2021

05:04PM EDT Alnylam Announces The Publication Of ILLUMINATE-A Phase 3 Study Results For Lumasiran In The New England Journal of Medicine Benzinga

Mar 29, 2021

08:00AM EDT Alnylam to Webcast Presentation at Stifel 3rd Annual CNS Day Business Wire

Mar 27, 2021

01:01PM EDT The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week Benzinga

Mar 23, 2021

08:11AM EDT Alnylam To Present Full 9-Month Results From The HELIOS-A Phase 3 Study Of Vutrisiran At The American Academy Of Neurology Virtual Annual Meeting 2021 Benzinga

08:03AM EDT Alnylam To Present Full 9-Month Results From HELIOS-A Phase 3 Study Of Vutrisiran At AAN Virtual Annual Meeting 2021 RTTNews

08:00AM EDT Alnylam to Present Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the American Academy of Neurology Virtual Annual Meeting 2021 Business Wire

Mar 17, 2021

11:47AM EDT Alnylam, Vir Biotech Deprioritize COVID-19 Drug Development In Hushed Manner Benzinga

Mar 11, 2021

08:30AM EST Alnylam Issues Inaugural Corporate Responsibility Summary Business Wire

Mar 9, 2021

09:17AM EST Alnylam Says Soleo Health To Administer Co's GIVLAARI For Treatment Of Acute Hepatic Porphyria In Adults Benzinga

Feb 22, 2021

04:00PM EST Alnylam to Webcast Presentations at Upcoming March Investor Conferences Business Wire

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2021 Benzinga

07:58AM EST Guggenheim Downgrades Alnylam Pharmaceuticals to Neutral, Announces $162 Price Target Benzinga

Feb 18, 2021

04:00PM EST Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference Business Wire

Feb 12, 2021

10:45AM EST Barclays Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $196 Benzinga

10:19AM EST Citigroup Downgrades Alnylam Pharmaceuticals to Neutral, Raises Price Target to $175 Benzinga

08:44AM EST 10 Biggest Price Target Changes For Friday Benzinga

08:03AM EST Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $206 Benzinga

06:53AM EST HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $235 Benzinga

06:43AM EST Needham Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $180 Benzinga

Feb 11, 2021

08:06AM EST Alnylam Q4 GAAP Loss/Shr $2.09 Vs Loss $2.47 Prior Year RTTNews

08:00AM EST Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity Business Wire

03:51AM EST Earnings Scheduled For February 11, 2021 Benzinga

Feb 10, 2021

10:52AM EST Preview: Alnylam Pharmaceuticals's Earnings Benzinga

Feb 6, 2021

12:42PM EST The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight Benzinga

Jan 28, 2021

08:01AM EST Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial Results Business Wire

Jan 27, 2021

07:36AM EST The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement Benzinga

Jan 26, 2021

08:07AM EST The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market Benzinga

Jan 25, 2021

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 25, 2021 Benzinga

07:46AM EST BMO Capital Downgrades Alnylam Pharmaceuticals to Market Perform, Announces $185 Price Target Benzinga

Jan 14, 2021

07:57AM EST The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates Benzinga

Jan 11, 2021

11:31AM EST Alnylam Pharmaceuticals Option Alert: Jun 18 $155 Calls Sweep (3) near the Ask: 16 @ $17.601 vs 8 OI; Earnings 2/4 Before Open [est] Ref=$149.71 Benzinga

Jan 10, 2021

01:00PM EST Alnylam Launches "Alnylam P5x25" Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over Next Five Years Business Wire

Jan 7, 2021

09:58AM EST Shares of Alnylam Pharmaceuticals Inc. (ALNY) are rising over 6% Thursday morning, after the company reported positive topline results from HELIOS-A Phase 3 Study of Vutrisiran in patients with hATTR Amyloidosis with Polyneuropathy. RTTNews

07:47AM EST Alnylam Pharmaceuticals, Inc. (ALNY) said Thursday that the HELIOS-A Phase 3 study of vutrisiran, met its primary and both secondary endpoints at nine months in patients with hATTR amyloidosis with polyneuropathy. RTTNews

07:06AM EST Alnylam Reports Positive Topline Results From HELIOS-A Phase 3 Study Of Vutrisiran RTTNews

07:02AM EST Alnylam Reports Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy Met Primary and All Secondary Endpoints at 9 Months, with Statistically Significant Improvements in Progression of Neuropathy Benzinga

07:00AM EST Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy Business Wire

Jan 6, 2021

05:23PM EST Vir Biotechnology And Alnylam Pharmaceuticals, Inc. Entered Into A Letter Amendment, Dated December 23, 2020; Amendment To Modify Certain Funding And Governance Provisions In Connection With RNAi Programs Benzinga

Jan 4, 2021

04:00PM EST Alnylam to Webcast Presentation at 39th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 21, 2020

08:09AM EST Alnylam Appoints Tolga Tanguler Chief Commercial Officer Benzinga

08:00AM EST Alnylam Appoints Tolga Tanguler Chief Commercial Officer and Also Announces New CEMEA, Medical Affairs, and Compliance Leaders Business Wire

Dec 16, 2020

07:15AM EST The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal Benzinga

Dec 15, 2020

07:28AM EST Alnylam Pharmaceuticals Inc. (ALNY) said that it plans to showcase its commercial and R&D progress at a virtual R&D Day event. It includes its product and pipeline goals for 2021, focused on continued commercial execution and advancement of early-, mid- and late-stage investigational programs. RTTNews

07:04AM EST Alnylam Says Remains On Track To Report Topline Results From The HELIOS-A Study Of Vutrisiran In Early 2021 RTTNews

07:00AM EST Alnylam Announces 2021 Product and Pipeline Goals and Provides Program Updates at R&D Day Business Wire

Dec 8, 2020

08:00AM EST Alnylam to Webcast Virtual R&D Day Business Wire

Dec 7, 2020

07:30AM EST Alnylam Issues 2nd Annual Patient Access Philosophy Report Highlighting Broad Access to the Company's Approved Therapies Business Wire

Dec 3, 2020

01:53PM EST OXLUMO(tm) (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels PR Newswire

08:10AM EST Alnylam Reports Full Patient Enrollment In Its ILLUMINATE-C Phase 3 Study Of Lumasiran RTTNews

08:09AM EST Orsini Specialty Pharmacy Expands Partnership With Alnylam As A Limited Distribution Partner For OXLUMO RTTNews

08:07AM EST Orsini Specialty Pharmacy Expands Partnership With Alnylam(r) Pharmaceuticals PR Newswire

08:00AM EST Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1 Business Wire

Nov 29, 2020

08:59AM EST The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions Benzinga

Nov 28, 2020

01:08PM EST Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates Benzinga

Nov 25, 2020

08:00AM EST Alnylam to Webcast Presentation at 43rd Nasdaq Virtual Investor Conference Business Wire

07:55AM EST Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $203 Benzinga

03:51AM EST SVB Leerink Maintains Market Perform on Alnylam Pharmaceuticals, Raises Price Target to $93 Benzinga

Nov 24, 2020

08:13AM EST The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia Benzinga

07:47AM EST The U.S. Food and Drug Administration approved the first drug to treat primary hyperoxaluria type 1 (PH1), an ultra-rare genetic disorder which causes recurrent kidney stones and loss of kidney function. RTTNews

07:10AM EST Alnylam Announces Innovative Value-Based Agreement Framework For OXLUMO RTTNews

07:07AM EST Alnylam: FDA Approves OXLUMO For PH1 To Lower Urinary Oxalate Levels In Pediatric, Adult Patients RTTNews

07:03AM EST Alnylam Announces FDA Approves OXLUMO, the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Pediatric and Adult Patients Benzinga

07:01AM EST Alnylam Announces Innovative Value-Based Agreement Framework for OXLUMO(tm) (lumasiran) to Accelerate Access for Patients with Primary Hyperoxaluria Type 1 and Deliver Ultra-Rare Orphan Disease Pricing Solutions to U.S. Payers Business Wire

07:00AM EST Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO(tm) (lumasiran), the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Pediatric and Adult Patients Business Wire

04:12AM EST SVB Leerink Maintains Market Perform on Alnylam Pharmaceuticals, Raises Price Target to $91 Benzinga

Nov 19, 2020

07:14AM EST Alnylam Pharmaceuticals, Inc. (ALNY) said the European Commission has granted marketing authorization for OXLUMO (lumasiran), an RNAi therapeutic, for the treatment of primary hyperoxaluria type 1 in all age groups. The approval is based on efficacy and safety findings from both the ILLUMINATE-A and ILLUMINATE-B Phase 3 studies of lumasiran. RTTNews

07:06AM EST Alnylam Receives Approval for OXLUMO (lumasiran) in the European Union for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups Benzinga

07:05AM EST Alnylam Pharma: European Commission Grants Marketing Authorization For OXLUMO For Primary Hyperoxaluria Type 1 RTTNews

07:00AM EST Alnylam Receives Approval for OXLUMO(tm) (lumasiran) in the European Union for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups Business Wire

Nov 13, 2020

09:44AM EST Alnylam Reports Promising Interim Results From Phase 1 RTTNews

09:06AM EST Alnylam Reports Positive Interim Results From Ongoing Phase 1 Study Of ALN-AGT Benzinga